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INTRODUCTION
Multiple sclerosis (MS) is a progressive chronic inflamma-
tory demyelinating disease of the central nervous system of
still unknown etiology, where genetic and environmental
factors (including infectious agents as a component), as well
as autoimmunity, may be involved (Compston and Coles,
2008). In Latvia, there are no recent internationally pub-
lished data on the MS prevalence rate, albeit the last study
showed it was the highest among other Baltic States and
rather close to the epidemiology within a “Fennoscandian
focus” of high MS prevalence (Kurtzke, 2000; Pugliatti et
al., 2006). It has been suggested that human endogenous
retroviruses (HERVs) could trigger the aetiopathogenesis of
MS, see e.g. (Blomberg et al., 2005). So-called “virus-like
particles” containing reverse transcriptase and retroviral
RNA have been reported by several research groups in
supernatants from cultured monocytes, B, T and lepto-
meningeal cells, as well as in cerebrospinal fluid and sera or
plasma from MS patients ( Perron et al., 1989; 1991; Haahr
et al., 1994; Munch et al., 1995; Christensen et al., 1997;
Perron et al., 1997; Garson et al., 1998; Christensen et al.,
1999; 2000; Serra et al., 2001; Christensen et al., 2002;
Dolei et al., 2002; Nowak et al., 2003; Christensen, 2005;
de Villiers et al., 2006; Arru et al., 2007). However, in
some studies they were also detected in blood from non-MS
individuals (Garson et al., 1998) including patients with
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Multiple sclerosis (MS) is a neurological disease of unknown aetiology. Several research groups
reported an increased level of human endogenous retroviruses HERV-W and HERV-H RNAs in
cerebrospinal fluid, plasma and supernatants of cell cultures from MS individuals. To quantify the
abundance of extracellular virion-associated HERV, RNAs in blood, plasma samples from Latvian
MS patients, patients with other neurological diseases (OND), as well as blood donors (BD), were
retrospectively studied by using both our previously published and newly developed quantitative
Real-time reverse transcription PCR assays (QPCRs) targeting different polymerase (pol) gene
regions of HERV-W and HERV-H. Unspecific signals due to incomplete removal of DNA were
monitored by running the assays with and without reverse transcription (RT±) in parallel. Accord-
ing to our score, a few MS, OND and healthy controls gave borderline signals simultaneously with
both newly developed HERV-H and HERV-W QPCRs, but the rest were negative. All borderline
positive samples also had small amounts of non-retroviral cellular mRNA with possible origin from
cell-free circulating RNA fragments, apoptotic bodies or exosomes, which can mimic the previ-
ously described virus-like particles. The results do not confirm the previous reports on prevalence
of HERV-H or -W virion-associated RNA in plasma of MS patients.
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other neurological diseases (OND) (Dolei et al., 2002). Ac-
cording to these data the detected retroviral RNAs prefera-
bly belong to the HERV-W or HERV-H groups (Perron et
al., 1997; Komurian-Pradel et al., 1999; Christensen et al.,
2000; Perron et al., 2000; Christensen, 2005). Nevertheless,
the real nature and functions of the observed particles are
still in need of clarification (Froussard, 1995). The goal of
this paper was to check the abundance of extracellular
HERV-W and HERV-H RNAs in blood circulation of MS
patients versus controls. We used both previously published
(Forsman et al., 2005) and newly developed sets of broadly
targeting, highly sensitive, quantitative reverse transcription
real-time PCRs (QPCRs).
MATERIALS AND METHODS
Special methodological precautions. There are many
methodological “pitfalls” in HERV molecular studies,
which in conjunction with highly sensitive techniques (e.g.,
QPCRs), may easily cause false-positive results. Even a sin-
gle human DNA molecule is a rich source of amplifiable
HERV sequences (Tristem, 2000; Gifford and Tristem,
2003). Thus, to avoid any reagent and sample contamina-
tion with exogenous human DNA from laboratory personnel
and environment we observed strict anti-contamination rou-
tines throughout the entire pre-PCR and PCR steps, which
were performed in physically separated rooms within
UV-protected laminar and PCR hoods (Lo and Chan, 2006;
Tamariz et al., 2006). All working surfaces and equipment
were frequently decontaminated with UV irradiation (Ou et
al., 1991) and DNA AWAY™/RNase AWAY® solutions
(Molecular BioProducts Inc., USA) or sodium hypochlorite
(bleach).
Clinical samples. Thirty-seven patients with MS (25 fe-
males, 12 males), 20 patients (8 females, 12 males) with
acute or chronic inflammatory demyelinating polyneuro-
pathies (IDP), 6 patients (3 females, 3 males) with other
non-inflammatory neurological disorders of the CNS
(ONIND), 17 patients (9 females, 8 males) with non-inflam-
matory peripheral neuropathies (majority of them spondylo-
genic radiculopathies) (NIPN) and 25 randomly selected
blood donors (BD) (13 females, 12 males) were included in
this investigation (Table 1). The 43 IDP, ONIND and NIPN
patients were collectively called OND (other neurological
diseases). The mean age of the patients with MS was 37
years (16–59 years), of the patients with IDP — 34 years
(15–61), of the patients with ONIND — 29 years (15–68),
of the patients with NIPN — 40 years (15–54) and of the
blood donors — 37 years (18–60). The cohorts were estab-
lished with the approval of the Ethics Committee of Rîga
Stradiòð University and all participants gave informed con-
sent before the examination. A clinical diagnosis of MS was
established according to the revised criteria of McDonald
(Polman et al., 2005). The patients were considered to have
acute inflammatory lesion (positive Gd-enhancing lesions)
when areas of hyperintensity, compared with surrounding
brain parenchyma, were recorded on a T1-weighted MRI
scan after i.v. injection of gadolinium-DTPA (0.1 mmol/kg
body weight). Active disease was defined as a clinical exac-
erbation and the presence of active inflammatory lesions on
MRI (positive Gd- enhancing lesions); quiescent (inactive)
disease phase was defined as a clinical remission in the re-
lapsing/remitting MS and as relative stability in the second-
ary progressive MS. All patients of the IDP group met the
criteria of Ashbury and Cornblath for the Guillain-Barré
syndrome and for chronic IDP (Asbury and Cornblath,
1990). The type of nerve damage was estimated by nerve
conduction studies.
In order to obtain virtually cell-free plasma all EDTA-
anticoagulated blood samples were centrifugated at 1600 
g for 10 min at 4 oC and supernatants were collected. This
was followed by a second centrifugation at 16 000  g for
10 min at 4 oC to completely remove any cellular debris.
The clarified plasma samples were further treated with 0.4
g/l recombinant ribonuclease A (RNase A)(Ambion, UK)
for 10 min at 37 °C to avoid any possible contamination by
cellular RNA-containing endogenous retroviral sequences
(Dolei et al., 2002).
RNA purification. The expected viral RNAs were ex-
tracted from 250 µl of plasma samples by using the Tri-
zol®LS Reagent (Invitrogen Life Technologies, USA), as
described by the manufacturer, with some modifications.
Briefly, to remove high molecular weight DNA, after addi-
tion of a sample to Trizol, an additional centrifugation at
12 000 × g for 10 minutes at 4 °C was performed. The
cleared solution was transferred to a clean tube and 100 µl
of 1-bromo-3-chloropropane (BCP) (Sigma-Aldrich, USA),
instead of chloroform, was added (Chomczynski and
Mackey, 1995). Prior to precipitation of the RNA with iso-
propanol, 15 µg of GlycoBlue (Ambion, UK) as a carrier
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T a b l e 1
PERSONS INCLUDED IN THE EXAMINATION
Patients with multiple sclerosis: MS 37





2) Secondary Progressive MSSP 4
a) in relapse
b) in relative stability
2
2
3) Primary Progressive MSPP 4
Other non-demyelinating neurological disorders of
CNS
ONIND 6
Inflammatory demyelinating polyneuropathy: IDP 20
1) Acute inflammatory demyelinating
polyneuropathy
14
2) Chronic inflammatory demyelinating
polyneuropathy
6
Non-inflammatory peripheral neuropathy NIPN 17
Blood donors BD 25
CNS, central nervous system
was added to the aqueous phase. Finally, the RNA pellet
was dissolved in 20 µl of RNase-free water. For all prepara-
tions 100 000 copies of an exogenous internal control (EIC)
pAW109 RNA (Applied Biosystems, USA) were doped to
the Trizol® LS reagent to monitor the efficiency of RNA
extraction, possible RNA degradation during DNase treat-
ment and presence of RT-PCR inhibitors. To eliminate pos-
sible DNA contamination, all RNA preparations (20 µl)
were rigorously treated with hyperactive, recombinant
DNase according to the manufacturer’s recommendations
for the TURBO DNA-freeTM kit (Ambion, UK).
RT-PCR assays. 10 µl of each plasma RNA sample was re-
verse transcribed (RT+) in a volume of 25 µl containing 50
mM Tris-HCl (pH 8.3), 10 mM dithiothreitol (Promega,
USA), 75 mM KCl, 3 mM MgCl2, 800 µM of each dNTP
(Amersham Pharmacia Biotech, Sweden), 265 ng of random
hexamer oligonucleotides (Amersham Pharmacia Biotech,
Sweden), 40 U of recombinant RNase Inhibitor (Promega,
USA) and 25U of StrataScript reverse transcriptase (Strata-
gene, USA) at 25 oC for 10 min, 42 oC for 60 min and 95
oC for 5 min followed by chilling on ice. Controls without
reverse transcription (RT-) to check for cellular DNA con-
tamination were included for every sample. For all subse-
quent QPCR reactions 2 µl of the cDNA sample was used
per 25 µl PCR reaction. Thus, to estimate the number of
HERV RNA copies per ml of plasma (viral loads), the num-
ber of copies per PCR reaction had to be multiplied with
100.
Prior to QPCRs 2 µl of each RT+ preparation was amplified
with a primer pair DM151/152 (Applied Biosystems, USA)
spanning an IL-1 region of synthetic EIC, as described by
the manufacturer. Additionally, all samples were analysed
by a “PAN-retrovirus” seminested PCR system with human
DNA as a positive amplification control (Perron et al.,
1997; Tuke et al., 1997). The resulting RT-PCR products
were respectively analysed by 1.5% or 2.5% agarose gel
electrophoresis with ethidium bromide staining.
The human tissue RNA panel from ClonTech (Human total
RNA master panel II, catalogue number K4008-1) was also
used for evaluation our new QPCRs. As described by the
manufacturer, each tissue RNA sample was pooled from
several persons, and thus represents an average. For each
RNA preparation, 2 µg RNA was used to produce 50 µl of
cDNA, as described above. In each subsequent QPCR reac-
tion, 2 µl of cDNA was used.
QPCRs. Two reverse transcriptase (RT) motif-based
HERV-H and -W group-specific QPCRs used in this study
were described earlier (Forsman et al., 2005) and two novel
confirmatory assays, targeting conserved portions of the
carboxyl- (HERV-W) and aminoterminal (HERV-H) por-
tions of the evolutionary conserved polymerase (pol) gene,
were developed and characterised according to the MIQE
guidelines (Bustin et al., 2009). Briefly, four consensus
primers and two TaqMan® (hydrolysis) dual-labeled probes
(Table 2) theoretically detecting the expression of a major-
ity of HERV-H and -W loci were designed from the multi-
ple alignments of HERV-W (Fig. 1) and HERV-H (Fig. 2)
pol genes generated by the ClustalW programme (Thomp-
son et al., 1994). The included proviral sequences were ob-
tained from the GenBank database using the BLAST net-
work server (Altschul et al., 1997), as also derived from the
RetroTector© bioinformatics programme (Sperber et al.,
2007; 2009) and the literature (Perron et al., 1997; Tristem,
2000; Kim, 2001; Jern et al., 2004; 2005).
The specificity of the selected oligonucleotides was verified
by BLAST searching, cloning of PCR products amplified
from genomic DNA and sequencing of a number of ran-
domly selected clones. The cloning frequencies of the
amplimers relative to target abundance in the human ge-
nome did not indicate predominant amplification of some
HERV loci against others (D. Uzameckis, unpublished re-
sults). The quantification was made by interpolation in stan-
dard curves of dilutions of synthetic, entire pol gene-con-
taining HERV-H (GenBank accession no. AF026252,
nucleotide positions 41-245) (Lindeskog et al., 1998) and
HERV-W (GenBank accession no. AF009668, nucleotide
positions 1680-2150) (Perron et al., 1997) plasmids (Inte-
grated DNA Technologues Inc., USA), as well as from a
previously constructed histone 3.3C plasmid control
(Andersson et al., 2005). All QPCR reactions were per-
formed in duplicates in a Corbett Rotorgene (Corbett Re-
search, Australia) real-time thermocycler in a total volume
of 25 µl, containing 1 × TaqMan PCR Universal Master
Mix, No UNG with 0.05U of HKTM-UNG Thermolabile
Uracil N-Glycosylase (EPICENTRE, USA) (Longo et al.,
1990; Pruvost et al., 2005) and 2 µl of each cDNA prepara-
tion. Reagent or non-template controls were performed be-
184 Proc. Latvian Acad. Sci., Section B, Vol. 70 (2016), No. 4.


























QPCRs, Real-time reverse transcription polymerase chain reaction assays; HERV, human endogenous retroviruses; IUPAC ambiguity codes: Y = C/T, R =
A/G, K = G/T, I = Inosin; *position of internal dark quencher
fore and after each clinical sample, as well as a correspond-
ing negative RT- control for each sample was included.
Optimal concentrations of the selected primers and
TaqMan® probes were determined according to the
TaqMan® PCR Universal Master Mix guidelines (Applied
Biosystems, USA) (data not shown). For subsequent QPCR
reactions final concentrations of 300 nM of each primer and
100 nM (HERV-W) or 200 nM (HERV-H) of the probe
were used (Table 2).
For HERV-W QPCR, the lowest threshold cycle (Ct) and
highest reduced normalised fluorescence (Rn) were ob-
served at 50 °C (data not shown). An optimal annealing
temperature of 50 °C was therefore chosen to broadly am-
plify many HERV-W loci. Final QPCR parameters were 50
°C for 3 min, 95 °C for 10 min, followed by 60 cycles of 95
°C for 15 s, 50 °C for 30 s and 72 °C for 30 s. During the
optimisation, gradient PCR reactions were performed at dif-
ferent annealing temperatures from 50 °C to 60 °C with an
increment of 1 °C. The same amount of human genomic
DNA (30 ng per PCR reaction) was used as a template dur-
ing all optimisation experiments.
For HERV-H QPCR, no significant difference in the thresh-
old cycles (Cts) or Rn was observed at different annealing
temperatures (data not shown). Final QPCR parameters
were 50 °C for 3 min, 95 °C for 10 min, 60 cycles of 95 °C
for 15 s and 60 °C for 1 min. The PCR optimisation proce-
dure was otherwise the same as described for HERV-W.
The linearity and sensitivity of the developed assays were
ascertained by generation of a standard curve with serial
plasmid DNA dilutions (100–107 copies/reaction with
10-fold increment). Although an exact quantification
through these real-time PCRs cannot be expected due to
measurement of DNA rather than RNA and frequent muta-
tions in primer and probe target sequences of members of
these two HERV groups, we subsequently refer to them as
quantitative PCRs (QPCRs). Sensitivity of both new assays
was 1–10 nucleic acid equivalents of plasmid DNA stan-
dards or down to 100 fg of human genomic DNA per PCR
reaction (data not shown), which corresponds to a detection
limit for the whole system of approximately 100–1000 viral
RNA copies per mL of plasma, conservatively counting one
HERV DNA copy equal to one HERV RNA copy. For sim-
plicity we use the word “RNA equivalents” for clinical sam-
ples even if the available standards were DNAs and the
QPCR reactions were preceded by a reverse transcription
step (two-step RT-PCR). Lacking a more precise quantifica-
tion, these correspond to “cDNA copies”.
The efficiencies of the developed HERV-H and HERV-W
QPCRs were 98% (slope –3.37, r2 > 0.99) and 95% (slope
–3.45, r2 > 0.99), respectively.
The obtained results were scored as:
(1). negative: if a RT+ signal lower than 10 nucleic acid
equivalents per PCR reaction was observed, or signals of
similar strength occurred in the RT+ and the RT- reactions;
(2). borderline: if the RT+ signal was from 10 till 99 nucleic
acid equivalents per PCR reaction and the RT- signal was
negative or less than 1/10 of the RT+ signal;
(3). clearly positive: if the RT+ signal was 100 nucleic acid
equivalents per PCR reaction or more, and the RT- signal
was negative or less than 1/10 of the RT+ signal.
In spite of a much lower RT- signal, there is a considerable
uncertainty in the borderline zone, both due to the stochastic
nature of the signal in this range and the somewhat uncer-
tain contribution of cellular DNA or cDNA to the signal. As
a confirmatory test, all QPCR products were electrophoreti-
cally resolved in 2% preparative agarose gels and stained
with ethidium bromide. The PCR results were obtained in
Uppsala before the identity of the samples was revealed
from Latvia.
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Fig. 1. Alignment of a conserved portion of the integrase domain at the carboxy terminus of the polymerase genes of selected representatives of the
HERV-W group. Sequences were obtained from the literature (Kim, 2001; Perron et al., 1997) and our own BLAST searches in Genbank. Genbank acces-
sion numbers: MSRV (AF009668) (translation was derived from it), HWX1 (AB021919), HWX3 (AB021920), HWX5 (AB021921), 45I4 (AL023581),
B353C18 (AC004066), B153K6 (AC005187), U134E6 (Z83850), Q11M15 (AF045450), RG083M05 (AC000064), BAC378 (U85196). HERV, human en-
dogenous retroviruses.
The QPCRs were also used to study HERV-H and
HERV-W expression in twenty different human tissues. No
RNA reference was used. In other studies, we measured his-
tone 3.3 C (Andersson et al., 2005), as also UBC, HPRT,
and GAPDH (Vandesompele et al., 2002) housekeeping
genes mRNA expression levels in the same tissue RNA
panel samples. The most evenly expressed gene per µg of
RNA was histone 3.3 C (data not shown). The relative ex-
pression pattern became essentially the same with and with-
out normalisation against histone 3.3 C. In this paper, we
therefore chose not to perform the normalisation.
Statistical analysis. The Freeman-Halton extension of
two-tailed Fisher’s exact test was used to analyse differ-
ences in categorical variables (Freeman and Halton, 1951;
Soper, 2015), as well as the nonparametric Kruskal-Wallis
analysis was implicated to compare the viral loads between
MS and control groups. Statistical differences were consid-
ered significant when p < 0.05.
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Fig. 2. Alignment of amino termini of HERV- H sequences. GenBank entries were partially obtained from Tristem (2000) and our own BLAST searches in
GenBank. HERV, human endogenous retroviruses.
RESULTS
The PCRs. Clearly visible 308-bp internal control ampli-
cons with similar band intensities were obtained from all
RT+ samples (data not shown) excluding any troubleshoot-
ing in RNA processing. All clinical samples included in the
study were negative with the PAN primers; however, the
human DNA controls included in the assay were highly pos-
itive (data not shown).
The QPCRs. Despite the extreme sensitivity of our HERV
QPCR assays down to few nucleic acid targets per PCR re-
action, almost all outcomes of these PCRs for plasma sam-
ples were either negative or borderline. Eight of 37 MS
(~21.6%) patients, one of 43 OND patients (~2.3%) and 3
of 25 blood donors (12.0%) were borderline reactive simul-
taneously with both our new HERV QPCRs and yielded
negative or significantly lower signals in RT- than in RT+
reactions, which were roughly equivalent to 11–28
HERV-H copies per PCR reaction (1100–2800 viral copies
per mL of plasma) and 39–74 HERV-W copies per PCR re-
action (3900–7400 viral copies per mL of plasma), respec-
tively (Table 3). The borderline positive sample in the OND
patients group with NIPN was from a patient with spondy-
logenic radiculopathy, who underwent spinal surgery due to
spinal stenosis one year before the investigation. All other
plasma samples were negative according to our scores. In
summary, 12 of 80 patient samples (15.0%) were borderline
reactive and 8 of them (10.0%) were in the MS group. How-
ever, histone 3.3C QPCR (Andersson et al., 2005) was reac-
tive in all of the HERV positive plasma samples, showing
the presence of certain cellular RNA transcripts. All border-
line reactive QPCR samples also showed weak bands of
sizes appropriate for the studied HERVs on agarose gels.
Moreover, all clearly negative samples were absolutely neg-
ative in gel electrophoresis analysis (data not shown). The
uncertain nature of the borderline reactivity, as also the
presence of histone 3.3 C positivity, make it hard to draw
definite conclusions from the results regarding the presence
of retroviral particles.
In contrast with plasma samples, the tissue specific expres-
sion of HERV-H and HERV-W was characterised by strong
QPCR signals and varied much. In concordance with our
previous studies, HERV-H showed the highest expression
in whole brain and testis, while the HERV-W group was
most expressed in whole brain, uterus, trachea, adrenal
gland, thyroid gland, prostate, spleen and placenta (Fig. 3)
(Forsman et al., 2005).
For all PCR assays, no contamination was observed in any
of the reagent control samples.
DISCUSSION
Our “story” with the controversial findings is suspiciously
similar to the reports of HRV-5, SV40 and XMRV
“epopees” when these viral sequences were false-positively
detected in clinical samples and misassociated with certain
human diseases (Griffiths et al., 2002; Forsman et al., 2003;
Shah, 2007; Elfaitouri et al., 2011; Arias and Fan, 2014). In
all these cases laboratory contamination was proposed as a
source of doubtful weakly positive results. However, the sit-
uation with HERVs is even more “dramatic”, because the
human genome contains over 3000 of amplifiable HERVs
copies (Lander et al., 2001). Recent ancient DNA studies
have shown the huge difficulties in creating a laboratory
virtually free of human DNA (Cooper and Poinar, 2000;
Knapp et al., 2012). Our very stringent precautions against
human and HERV DNA contamination may be the explana-
tion of the true-negative or borderline PCR results. Addi-
tionally, frequent presence of animal and human DNA con-
tamination of different molecular biology reagents
(including those for PCRs) and laboratory consumables
from different vendors has been reported (Cooper and
Poinar, 2000; Leonard, 2007; Gefrides et al., 2010). As an
example, the native reverse transcriptases (e.g., ALV,
MuLV), which were used in some previously published
studies, in contrast to recombinant enzymes (in our case),
can contain the retroviral sequences and cause false-positive
RT-PCR results with broadly amplifying primers (Perron et
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2019 ± 409 1100 ± 100 1917 ± 417
HERV-W:
(copies/mL)
5788 ± 850 3900 ± 100 5733 ± 867
QPCRs, Real-time reverse transcription PCR assays; HERV, human endogenous retroviruses; see abbreviations also in Table 1; *Histone 3.3C positivity
al., 1997; Tuke et al., 1997). The weakness or negativity of
the observed QPCR signals can be also due to the usage of a
novel, hyperreactive variant of DNase I (TURBOTM
DNase), thus, according to the manufacturer’s data, the re-
moval of possible DNA contamination prior to cDNA syn-
thesis was up to 50-times more effective than in the previ-
ous studies where conventional, wild-type enzyme was
used.
It is also known that, in spite of high activity of RNases in
human body fluids, free circulating extracellular RNAs
somehow are protected from degradation and may occur in
cell-free plasma of both healthy and diseased humans
(Kamm and Smith, 1972; Wieczorek et al., 1985; 1987).
Thus, the borderline HERV QPCR signals detected in
plasma even after extensive RNase treatment may contain a
contribution from this RNA type, of which HERV tran-
scripts may be a normal, but not the major or obligatory
component. We also propose that the apoptotic bodies from
dying, aged or damaged cells (Hasselmann et al., 2001;
El-Hefnawy et al., 2004), as well as other extracellular vesi-
cles (e.g., exosomes and microvesicles), which are also
known to occur in plasma and serum (El-Hefnawy et al.,
2004), may mimic retroviral particles in which HERV RNA
could be protected from ribonucleases. Thus, artefactual
PCR detection of HERV RNA in “virions” may explain the
previous reports on HERV RNA in “retroviral particles”.
Unfortunately, in spite of the strong evidence about highly
elevated levels of circulating DNA and main microRNAs
(miRNAs) in MS plasma (Liggett et al., 2010; Siegel et al.,
2012), there are no adequate data about the cell-free circu-
lating RNA (cfcRNA) fraction (Unger et al., 1985) and its
HERV component(s) in MS at the moment. Nevertheless,
the release of microvesicles enriched in HERV nucleic ac-
ids and RT was found in the plasma of some cancer pa-
tients, as also media supernatants from certain cultured tu-
mour cells (Bronson et al., 1979; Seifarth et al., 1995;
Contreras-Galindo et al., 2008; Balaj et al., 2011). One
more explanation of our negative or borderline QPCR re-
sults also could be due to occasional absence of detection
because of mismatch(es) between the cDNA targets and
primers or hydrolysis (TaqMan®) probes due to frequent
mutations in HERV-H and HERV-W pol genes (Jern et al.,
2004). However, the agarose gel electrophoresis analysis of
all QPCR products, as well as highly positive, reproducible
results with human tissue RNAs do not confirm this as-
sumption (Fig. 3). The EIC also controlled for inadequate
RNA extraction, degradation of isolated RNA during treat-
ment with DNase, presence of reverse transcription and/or
PCR inhibitors, as well as negligence or serious technical
errors. Our findings do not exclude the presence of low
amounts of retroviral RNA-containing particles (e.g., exo-
somes) in systemic circulation of MS patients, but advocate
that this disease does not involve a systemic intense virus-
like particle- or non-particle-associated HERV RNAemia.
In this case, the concentration of virus-like particles on col-
umns or gradients from a much more large volume of
plasma would be very useful methodological approach. Ad-
ditionally, some noteworthy data do not confirm the tran-
scriptional activity of HERV-W in MS (Antony et al., 2006;
Laufer et al., 2009; Schmitt et al., 2013) and even existence
of so intensively studied Multiple Sclerosis Associated Ret-
rovirus (MSRV) in vivo (Flockerzi et al., 2007; Laufer et
al., 2009; Schmitt et al., 2013). Indeed, an absence of
HERV-W or/and HERV-H RNA detection for MS plasma
and CSF was reported (Antony et al., 2007; Alvarez-
Lafuente et al., 2008). Moreover, in one study (Alvarez-
Lafuente et al., 2008) our previously published (also used in
the present work) QPCR assays were used (Forsman et al.,
2005). It is hard to exclude that the negativity of the same
PCR methods in our study could be due to the absence of
detection of certain HERV loci. In literature, there is no
convincing evidence for HERV capability to cause “virione-
mia” and the term “retrovirus-like particles” is overused.
However, our study does not allow us to exclude that a low
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Fig. 3. Expression of HERV-H and HERV-W in twenty human tissues studied with new HERV-W (A) and HERV-H (B) QPCRs. HERV, human endogenous
retroviruses. QPCRs, Real-time reverse transcription PCR assays.
number of microvesicles from human biological fluids may
indeed be of retroviral origin (Muralidharan-Chari et al.,
2009).
In agreement with previous data our study also shows some
upregulation of HERV-H and -W RNAs in MS plasma
(21.6%) versus controls (5.9%) (p = 0.02, Fisher Exact test),
but the control group was too heterogeneous, which compli-
cates the interpretation. The “retroviral loads” of the sam-
ples which yielded a positive result were 2019 ± 409 vs
1713 ± 513 copies/mL (MS vs controls) for HERV-H and
5788 ± 850 vs 5275 ± 1075 copies/mL (MS vs controls) for
HERV-W. They were not significantly different with p <
0.05, using the Kruskal-Wallis test. The HERV signals were
likely of cellular origin. It is natural that cellular debris,
apoptotic blebs or exosomes occur in an autoimmune dis-
ease, which inherently involves an increased frequency of
cell death. No difference in the frequency of HERV-W and
HERV-H RNA between different forms and stages of MS
was observed (data not shown). In spite of the simultaneous
detection of both HERVs in all positive clinical samples,
the similar QPCRs efficiencies and detection limits, as well
as the higher HERV-H versus HERV-W proviral loci num-
ber (660 and 115 copies per haploid genome, respectively)
(Tristem, 2000), their “viral loads” were different
(HERV-W > HERV-H, 5617 ± 926 vs 1917 ± 436 cop-
ies/mL). Possible explanations of this phenomenon may be
lower transcriptional activity of HERV-H loci, a broader
range for the new HERV-W QPCRs, or preferable incorpo-
ration of HERV-W transcripts into viral particles or extra-
cellular vesicles. We speculate that the previously reported
“retroviral particles” were exosomes, due to their similar
size (100 nm) and buoyant density in a sucrose gradient
(Thery et al., 2006), albeit some data posit the presence of
these particles and reverse transcriptase activity in different
fractions (Froussard, 1995). Thus, to clarify the origin of
HERV RNA transcripts in diseased and healthy human
plasma, cfcRNA, miRNAs, retrovirus-like particles (proba-
bly exosomes) and microvesicles should be individually
isolated and carefully analysed for their retroviral compo-
nents. Theoretically, we also cannot exclude the existence
of real HERV virions co-packaged with cell RNAs (Greijer
et al., 2000; Sciortino et al., 2001) and even the formation
of complex chimeric virions containing a “cocktail” of mul-
tiple retroviral RNAs (e.g. HERV-H and -W together) with
cellular transcripts in vivo. However, in our opinion, the low
“viral loads” and simultaneous detection of both HERVs
and nonretroviral RNAs in the MS samples makes it rather
hard to attribute the QPCRs findings to the production of
virions. We may speculate that the previous findings were
experimental artifacts or drafts due to laboratory flaws.
Even in our hands, while we rigorously removed DNA from
RNA preparations and very carefully verified the absence of
DNA contamination in all QPCR experiments, it is never-
theless very difficult to remove all DNA traces from RNA
preparations. One therefore cannot formally exclude the
presence of some residual DNA in the RNA used for cDNA
generation. Moreover, the effect of interindividual varia-
tions (Nellaker et al., 2009), ethnical (Arru et al., 2007),
age- and therapy-specific factors (Diem et al., 2012; Liu et
al., 2013; Arru et al., 2014; Balestrieri et al., 2015), as also
MS clinical forms and disease severity (Garcia-Montojo et
al., 2013; 2014) on the expression and release of HERV
RNAs into the bloodstream cannot be excluded. Thus, one
of the falsification criteria for one of the models for retrovi-
rally caused disease in MS may be fulfilled (Blomberg et
al., 2005). The optimised methods can be useful for under-
standing of the pathobiology of HERV-H and HERV-W.
The study also illustrates the methodological difficulties of
getting and interpreting reliable HERV PCR results, espe-
cially in patients with cytopathic diseases. In our opinion, to
further elucidate the possible physiopathological functions
of HERVs, there is a need for several carefully designed,
preferably prospective, studies methodologically harmo-
nised between all investigators.
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NAV APSTIPRINOÐU PIERÂDÎJUMU PAR ENDOGÇNO RETROVÎRUSU HERV-W UN HERV-H RNS SASTOPAMÎBU LATVIJAS
PACIENTU AR MULTIPLO SKLEROZI UN CITÂM NEIROLOÌISKÂM SLIMÎBÂM ASINS PLAZMÂ
Multiplâ skleroze (MS) ir neiroloìiska slimîba ar nezinâmu etioloìiju. Daþas pçtnieku grupas ir ziòojuðas par divu cilvçka endogçno
retrovîrusu HERV-W un HERV-H paaugstinâtu RNS lîmeni cerebrospinâlajâ ðíidrumâ, asins plazmâ un ðûnu kultûru supernatantâ, kas
iegûti no MS pacientiem. Abu HERV ekstracelulâro vîrusspecifisko RNS kvantitatîvai noteikðanai Latvijas MS pacientu un pacientu ar
citâm neiroloìiskâm slimîbâm asins plazmas paraugos tika lietotas gan mûsu iepriekð publicçtas, gan arî jaunizstrâdâtas kvantitatîvas reâlâ
laika apgrieztâs transkripcijas PCR (polymerase chain reaction, polimerâzes íçdes reakcija) metodes (QPCRs) ar praimeriem un zondçm,
kas ir komplementâras daþâdiem HERV-W un HERV-H polimerâzes (pol) gçna rajoniem. Lai izslçgtu nespecifisku HERV signâlu
esamîbu, kas rodas sakarâ ar nepilnîgu ðûnu DNS degradçðanu RNS paraugos, paralçli tika veiktas QPCRs ar un bez apgrieztâs
transkripcijas posma (RT±). Atbilstoði mûsu kritçrijiem, daþi MS un kontroles grupu paraugi bija robeþpozitîvi vienlaikus abâs
jaunizstrâdâtajâs HERV-H un HERV-W QPCRs, bet pârçjie bija negatîvi. Visi ðie robeþpozitîvie paraugi saturçja nelielu ðûnu iRNS
daudzumu ar iespçjamu izcelsmi no asinîs cirkulçjoðas ðûnâm brîvas RNS, apoptotiskiem íermenîðiem vai ekzosomâm, kas var mimikrçt
iepriekð aprakstîtâs vîrusiem lîdzîgâs daïiòas. Iegûtie rezultâti neapstiprina iepriekð publicçtos datus par HERV-H un HERV-W
vîrusasociçtâs RNS sastopamîbu MS pacientu asins plazmâ.
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